JPWO2020186238A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020186238A5 JPWO2020186238A5 JP2021553296A JP2021553296A JPWO2020186238A5 JP WO2020186238 A5 JPWO2020186238 A5 JP WO2020186238A5 JP 2021553296 A JP2021553296 A JP 2021553296A JP 2021553296 A JP2021553296 A JP 2021553296A JP WO2020186238 A5 JPWO2020186238 A5 JP WO2020186238A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- seq
- cancer
- sequence selected
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 108091033319 polynucleotide Proteins 0.000 claims description 36
- 102000040430 polynucleotide Human genes 0.000 claims description 36
- 239000002157 polynucleotide Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 12
- 101150027249 RL1 gene Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000001018 virulence Effects 0.000 claims description 12
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 101150026402 DBP gene Proteins 0.000 claims description 4
- 230000003682 DNA packaging effect Effects 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 4
- 101150090364 ICP0 gene Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000520 microinjection Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 108010040614 terminase Proteins 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 101001042070 Equine herpesvirus 1 (strain V592) E3 ubiquitin-protein ligase ICP0 Proteins 0.000 claims description 2
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 108091092195 Intron Proteins 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000011319 anticancer therapy Methods 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000037433 frameshift Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000009095 third-line therapy Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218272A JP2025028186A (ja) | 2019-03-14 | 2024-12-12 | 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818577P | 2019-03-14 | 2019-03-14 | |
| US62/818,577 | 2019-03-14 | ||
| US201962932725P | 2019-11-08 | 2019-11-08 | |
| US62/932,725 | 2019-11-08 | ||
| PCT/US2020/022806 WO2020186238A1 (en) | 2019-03-14 | 2020-03-13 | Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218272A Division JP2025028186A (ja) | 2019-03-14 | 2024-12-12 | 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022524379A JP2022524379A (ja) | 2022-05-02 |
| JP2022524379A5 JP2022524379A5 (https=) | 2023-03-20 |
| JPWO2020186238A5 true JPWO2020186238A5 (https=) | 2023-03-20 |
| JP7671253B2 JP7671253B2 (ja) | 2025-05-01 |
Family
ID=72426047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553296A Active JP7671253B2 (ja) | 2019-03-14 | 2020-03-13 | 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 |
| JP2024218272A Pending JP2025028186A (ja) | 2019-03-14 | 2024-12-12 | 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218272A Pending JP2025028186A (ja) | 2019-03-14 | 2024-12-12 | 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12480097B2 (https=) |
| EP (1) | EP3937960A4 (https=) |
| JP (2) | JP7671253B2 (https=) |
| KR (1) | KR102933002B1 (https=) |
| CN (1) | CN113710259B (https=) |
| AU (1) | AU2020235140B2 (https=) |
| BR (1) | BR112021017651A2 (https=) |
| CA (1) | CA3132867A1 (https=) |
| IL (1) | IL286142B2 (https=) |
| SG (1) | SG11202109707VA (https=) |
| WO (1) | WO2020186238A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120380154A (zh) * | 2022-12-14 | 2025-07-25 | Eg427公司 | 改良型单纯疱疹病毒1型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL131212A0 (en) * | 1999-08-03 | 2001-01-28 | Yissum Res Dev Co | Recombinant virus and live-virus vaccines |
| WO2005005637A2 (en) * | 2003-05-09 | 2005-01-20 | Medigene, Inc. | Herpes simplex virus comprising a genetically modified glycoprotein d |
| JP5639361B2 (ja) * | 2006-09-08 | 2014-12-10 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法 |
| JP6726824B2 (ja) * | 2013-07-17 | 2020-07-22 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| JP6865736B2 (ja) * | 2015-05-04 | 2021-04-28 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 腫瘍溶解性ｈｓｖ１ベクターおよび使用法 |
| US10596234B2 (en) | 2016-10-28 | 2020-03-24 | University Of Southern California | Compositions and methods to inhibit viral replication |
| JP7490365B2 (ja) * | 2017-03-09 | 2024-05-27 | シァメン・ユニヴァーシティ | 組み換え単純ヘルペスウイルス及びその使用 |
-
2020
- 2020-03-13 CN CN202080032165.0A patent/CN113710259B/zh active Active
- 2020-03-13 CA CA3132867A patent/CA3132867A1/en active Pending
- 2020-03-13 SG SG11202109707V patent/SG11202109707VA/en unknown
- 2020-03-13 BR BR112021017651A patent/BR112021017651A2/pt unknown
- 2020-03-13 US US17/438,877 patent/US12480097B2/en active Active
- 2020-03-13 AU AU2020235140A patent/AU2020235140B2/en active Active
- 2020-03-13 IL IL286142A patent/IL286142B2/en unknown
- 2020-03-13 JP JP2021553296A patent/JP7671253B2/ja active Active
- 2020-03-13 KR KR1020217031853A patent/KR102933002B1/ko active Active
- 2020-03-13 EP EP20769295.5A patent/EP3937960A4/en active Pending
- 2020-03-13 WO PCT/US2020/022806 patent/WO2020186238A1/en not_active Ceased
-
2024
- 2024-12-12 JP JP2024218272A patent/JP2025028186A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230152689A (ko) | 유전자 침묵 | |
| WO2016198500A1 (en) | Methods and compositions for rna-guided treatment of human cytomegalovirus (hcmv) infection | |
| JPH09503902A (ja) | 組み換えウイルス免疫治療 | |
| JP2021522837A (ja) | 造血幹細胞移植のための組成物及び方法 | |
| US20250313606A1 (en) | T cell receptors targeting pik3ca mutations and uses thereof | |
| Riddell et al. | Minor histocompatibility antigens-targets of graft versus leukemia responses | |
| JP2025061710A (ja) | Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用 | |
| JP2005519591A (ja) | 毛包成長 | |
| CN113336829B (zh) | 靶向anp32a抗白血病的小分子肽及其制备方法和应用 | |
| CN118063584A (zh) | 促肿瘤焦亡蛋白、靶向her2免疫促肿瘤焦亡蛋白及其编码基因与应用 | |
| JPH03505039A (ja) | 可溶性ｃｄ４を発現するレトロウイルスベクター、エイズの遺伝子治療法 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN116590237B (zh) | 一种遗传修饰的自然杀伤细胞及其制备和用途 | |
| JPWO2020186238A5 (https=) | ||
| Coupar et al. | Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. | |
| US20250154466A1 (en) | Combination bcl11a enhancer editing | |
| RU2021129248A (ru) | Синцитиальные онколитические мутанты herpes simplex в качестве мощных терапевтических средств для лечения рака | |
| Lupker et al. | Abundant excretion of human growth hormone by recombinant-plasmid-transformed monkey kidney cells | |
| CN114712393B (zh) | Hnf-1α基因修饰的间充质干细胞在防治肝癌中的用途 | |
| JPH09510357A (ja) | 酸性繊維芽細胞成長因子（ａＦＧＦ）をコードする組み換えアデノウィルス | |
| WO2021222451A2 (en) | Tagged gene editing technology for clinical cell sorting and enrichment | |
| Larsen et al. | Lymphoproliferative disorders: prospects for gene therapy | |
| CN112538108B (zh) | 高亲和pvr突变体 | |
| RU2552609C1 (ru) | Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов | |
| KR102616012B1 (ko) | 당화된 돼지 인터페론-알파를 발현하는 재조합 베큘로바이러스 |